{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"13"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"17"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"87"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"82"}],"title":"Failures"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"112"},{"groupId":"OG003","value":"112"}],"units":"Participants"}],"description":"Assessed by RECIST, each patient will have a pre-therapy baseline radiographic tumor measurement, preferably by MRI, however if logistic or practical or financial issues preclude MRI use, mammogram or ultrasound may be substituted. The longest diameter (LD) of the target lesion at the time of study initiation will be reported as the baseline LD. The baseline LD of the target lesion will be used as reference to further characterize the objective tumor response of the measurable dimension of the disease. Radiographic complete response: Disappearance of the target lesion. Radiographic partial response (PR): At least a 30% decrease in the longest diameter (LD) of the target lesion taking as reference the baseline LD.","groups":[{"description":"Patients receive paclitaxel (pac) IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV","id":"OG000","title":"Arm 1 (Pac --> ddAC)"},{"description":"Patients receive pac and ddAC as in arm 1. Patients also receive bevacizumab (bev) IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV\n\nbevacizumab: Given IV","id":"OG001","title":"Arm 2 (Pac + Bev --> ddAC + Bev)"},{"description":"Patients receive pac and ddAC as in arm 1. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV\n\ncarboplatin: Given IV","id":"OG002","title":"Arm 3 (Pac + Carboplatin --> ddAC)"},{"description":"Patients receive pac and ddAC as in arm 1, bev as in arm 2, and carboplatin as in arm 3.\n\ndoxorubicin hydrochloride: Given IV\n\npaclitaxel: Given IV\n\ncyclophosphamide: Given IV\n\nbevacizumab: Given IV\n\ncarboplatin: Given IV","id":"OG003","title":"Arm 4 (Pac + Carboplatin + Bev --> ddAC + Bev)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Baseline; at completion of neoadjuvant therapy","title":"Radiographic Response Assessed by Tumor Measurement","type":"SECONDARY","unitOfMeasure":"Participants"}